OR WAIT null SECS
- About Us
- Advertise
- Editorial Information
- Contact Us
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2024 MJH Life Sciences™ and BioPharm International. All rights reserved.
Emergence Therapeutics to License Synaffix ADC Technology Platform in Deal Worth Up to $360 Million
Emergence Therapeutics will work with Synaffix’s ADC technology platform to develop multiple ADCs against undisclosed targets.
Syanffix, a provider of clinical-stage platform technology, and Emergence Therapeutics, a biopharmaceutical company researching targets through antibody-drug conjugates (ADCs), announced a licensing agreement worth up to $360 million on Sept. 6, 2022. The agreement grants Emergence target-specific access to Synaffix’s portfolio of ADC platform technologies; this includes GlyoConnect, HydraSpace, and SYNtecan E linker-payload.
According to a company press release, Emergence will be responsible for the research, development, manufacturing, and commercialization of the ADCs, while Synaffix will manufacture components that are specifically related to its proprietary technologies. Payment of the full $360 million is contingent on achievement of various development, regulatory, and commercial milestones. In addition to these payments, Synaffix is also eligible to receive royalties on commercial sales.
“This transaction demonstrates our commitment to the development of our pipeline of first-in-class and/or best-in-class ADCs,” said Jack Elands, CEO, Emergence Therapeutics, in the press release. “Beyond our lead program ETx-22, a next generation Nectin-4 ADC, we are actively advancing further programs to develop treatments for high unmet-need cancers. We are impressed with the Synaffix technology and are pleased to select it as a key component to accelerate our pipeline of ADCs.”
“This marks an important milestone for Synaffix as this is the 10th ADC developer who has licensed our innovative ADC technology to develop proprietary ADCs for their own pipeline,” said Peter van de Sande, CEO, Synaffix, in the press release. “By consolidating all essential technologies within Synaffix, we have repeatedly enabled the development of best-in-class and first-in-class ADCs under a single technology license agreement. We are thrilled that Emergence has selected Synaffix as its long-term ADC technology partner and look forward to working closely with Emergence as they build out their portfolio of ADC candidates.”
Source: Synaffix
Related Content:
